Literature DB >> 10234091

Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics.

.   

Abstract

Changes in hemodynamics, caused by the inherent variability of the activity and awake-sleep cycle, may influence the outcome of various cardiovascular diseases. Recent data suggest that increased variability of blood pressure may promote excessive hypertensive target-organ disease. Several epidemiologic studies have demonstrated that myocardial ischemia, myocardial infarction, and sudden cardiac death have an excess incidence in the first several hours after awakening. In addition, surveys of the incidence of stroke (both ischemic and hemorrhagic) have shown an excess for the hours between 0800 a.m. and noon. The pathophysiologic bases for the increased number of cardiac and cerebrovascular events in the early-morning hours may be both hemodynamic and rheologic in nature. Over the past several years, therapeutic studies have evaluated the effects of antihypertensive and anti-ischemic therapies during the morning surge of blood pressure and heart rate. Generally, the few studies that have evaluated night-time dosing of conventional antihypertensive therapies have been statistically underpowered to demonstrate differences of morning versus evening dosing on early-morning blood pressure. One future direction of antihypertensive and anti-ischemic therapy is the delivery of the agents according to inherent variability that changes with time. The clinical impact of cardiovascular chronotherapy is that drug delivery is greatest when disease activity is enhanced (for example, during the early-morning hours) and least when disease activity is reduced.

Entities:  

Year:  1997        PMID: 10234091

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  9 in total

Review 1.  Chronotherapeutics for cardiovascular disease.

Authors:  Y A Anwar; W B White
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 2.  Desirable therapeutic characteristics of an optimal antihypertensive agent.

Authors:  Lisa Mustone Alexander
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?

Authors:  William B White; Spyridoula Maraka
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

Review 4.  Managing hypertension with ambulatory blood pressure monitoring.

Authors:  William B White; Vinay Gulati
Journal:  Curr Cardiol Rep       Date:  2015-02       Impact factor: 2.931

5.  Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.

Authors:  Hans R Brunner; Kikuo Arakawa
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 6.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

Review 7.  Does the timing of aspirin administration influence its antiplatelet effect - review of literature on chronotherapy.

Authors:  Ewa Miciak-Ławicka; Beata Begier-Krasińska; Andrzej Tykarski; Zbigniew Krasiński
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-06-25

8.  The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients-a randomized, controlled trial.

Authors:  Beata Krasińska; Lech Paluszkiewicz; Ewa Miciak-Ławicka; Maciej Krasinski; Piotr Rzymski; Andrzej Tykarski; Zbigniew Krasiński
Journal:  Eur J Clin Pharmacol       Date:  2020-09-21       Impact factor: 2.953

9.  Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.

Authors:  Joel M Neutel; William J Elliott; Joseph L Izzo; Chao L Chen; Harvey N Masonson
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Sep-Oct       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.